BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+39.76%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.54B
AUM Growth
+$2.54B
(+38%)
Cap. Flow
-$14.3M
Cap. Flow
% of AUM
-0.56%
Top 10 Holdings %
Top 10 Hldgs %
54.04%
Holding
74
New
12
Increased
15
Reduced
24
Closed
6
Top Buys
| 1 |
Olema Pharmaceuticals
OLMA
|
$320M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$47.2M |
| 3 |
4D Molecular Therapeutics
FDMT
|
$45.8M |
| 4 |
Protagonist Therapeutics
PTGX
|
$38.3M |
| 5 |
Lexicon Pharmaceuticals
LXRX
|
$37.5M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$164M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$119M |
| 3 |
Celldex Therapeutics
CLDX
|
$45.5M |
| 4 |
Eledon Pharmaceuticals
ELDN
|
$42.4M |
| 5 |
Replimune Group
REPL
|
$38.9M |
Sector Composition
| 1 | Healthcare | 98.24% |
| 2 | Financials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Olema Pharmaceuticals
OLMA
$444M
| $320M | 12.6% |
+6,661,503
| New | +$320M |
|
2
Xoma
XOMA
$420M
| $185M | 7.26% |
4,182,243
| – | – |
|
3
Kymera Therapeutics
KYMR
$2.91B
| $163M | 6.42% |
2,630,658
| – | – |
|
4
Relay Therapeutics
RLAY
$631M
| $128M | 5.02% |
3,073,147
-305,233
| -9% | -$12.7M |
|
5
Revolution Medicines
RVMD
$7.39B
| $110M | 4.31% |
2,768,049
+667,000
| +32% | +$26.4M |
|
6
Repare Therapeutics
RPTX
$73M
| $102M | 4.01% |
2,972,191
-92,543
| -3% | -$3.17M |
|
7
Merus
MRUS
$5.01B
| $102M | 4% |
5,805,571
+160,000
| +3% | +$2.8M |
|
8
Cytokinetics
CYTK
$5.94B
| $101M | 3.99% |
4,878,035
+1,554,984
| +47% | +$32.3M |
|
|
9
Protagonist Therapeutics
PTGX
$3.66B
| $86.2M | 3.39% |
4,273,588
+1,901,300
| +80% | +$38.3M |
|
10
Ionis Pharmaceuticals
IONS
$9.16B
| $77.1M | 3.04% |
1,364,461
+629,406
| +86% | +$35.6M |
|
11
Arcus Biosciences
RCUS
$1.15B
| $71.4M | 2.81% |
2,752,222
+155,000
| +6% | +$4.02M |
|
12
Xencor
XNCR
$610M
| $55.2M | 2.17% |
1,264,754
-803,344
| -39% | -$35M |
|
13
Xenon Pharmaceuticals
XENE
$3.03B
| $53.8M | 2.12% |
3,499,346
| – | – |
|
|
AMRN
14
Amarin Corp
AMRN
$314M
| $52.6M | 2.07% |
10,761,593
+9,661,593
| +878% | +$47.2M |
|
15
AC Immune
ACIU
$222M
| $50.8M | 2% |
9,816,658
-2,100
| -0% | -$10.9K |
|
16
ALX Oncology
ALXO
$55.2M
| $46.6M | 1.83% |
540,837
-98,091
| -15% | -$8.46M |
|
|
17
4D Molecular Therapeutics
FDMT
$287M
| $45.8M | 1.8% |
+1,106,070
| New | +$45.8M |
|
18
IDEAYA Biosciences
IDYA
$2.23B
| $45.2M | 1.78% |
3,226,769
| – | – |
|
19
ESSA Pharma
EPIX
$11.3M
| $44.2M | 1.74% |
3,705,289
+699,700
| +23% | +$8.35M |
|
20
Spero Therapeutics
SPRO
$115M
| $43.5M | 1.71% |
2,243,278
+898,944
| +67% | +$17.4M |
|
21
Kura Oncology
KURA
$690M
| $40.7M | 1.6% |
1,245,912
-243,200
| -16% | -$7.94M |
|
22
Sutro Biopharma
STRO
$80.6M
| $40.3M | 1.58% |
1,854,162
-1,233,033
| -40% | -$26.8M |
|
|
23
Lexicon Pharmaceuticals
LXRX
$407M
| $37.5M | 1.48% |
+10,963,000
| New | +$37.5M |
|
|
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $36.9M | 1.45% |
17,426,968
| – | – |
|
25
CytomX Therapeutics
CTMX
$343M
| $36.5M | 1.44% |
5,576,471
+2,016,749
| +57% | +$13.2M |
|